Published in Lab Invest on August 04, 2008
Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3-dependent mechanism in mice. Circulation (2009) 1.75
The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal (2010) 1.72
Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol (2009) 1.43
A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells. Nat Commun (2013) 1.35
Hydrogen sulfide and ischemia-reperfusion injury. Pharmacol Res (2010) 1.31
Bench-to-bedside review: Hydrogen sulfide--the third gaseous transmitter: applications for critical care. Crit Care (2009) 1.31
Hydrogen sulfide-induced hypometabolism prevents renal ischemia/reperfusion injury. J Am Soc Nephrol (2009) 1.25
Cystathionine γ-lyase protects against renal ischemia/reperfusion by modulating oxidative stress. J Am Soc Nephrol (2013) 1.16
Hydrogen sulfide inhibits high glucose-induced matrix protein synthesis by activating AMP-activated protein kinase in renal epithelial cells. J Biol Chem (2011) 1.12
Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats. Crit Care (2010) 1.08
Signaling molecules: hydrogen sulfide and polysulfide. Antioxid Redox Signal (2014) 1.07
Hydrogen sulfide inhibits the renal fibrosis of obstructive nephropathy. Kidney Int (2013) 1.05
Hydrogen sulfide lowers proliferation and induces protective autophagy in colon epithelial cells. PLoS One (2012) 1.01
Hydrogen sulfide preconditioning or neutrophil depletion attenuates ischemia-reperfusion-induced mitochondrial dysfunction in rat small intestine. Am J Physiol Gastrointest Liver Physiol (2011) 1.01
Hydrogen sulfide preconditioning protects rat liver against ischemia/reperfusion injury by activating Akt-GSK-3β signaling and inhibiting mitochondrial permeability transition. PLoS One (2013) 0.97
Hydrogen sulfide is an endogenous potentiator of T cell activation. J Biol Chem (2011) 0.96
Production and actions of hydrogen sulfide, a novel gaseous bioactive substance, in the kidneys. J Pharmacol Exp Ther (2009) 0.96
Distribution of hydrogen sulfide (H₂S)-producing enzymes and the roles of the H₂S donor sodium hydrosulfide in diabetic nephropathy. Clin Exp Nephrol (2012) 0.95
H(2)S inhibits hyperglycemia-induced intrarenal renin-angiotensin system activation via attenuation of reactive oxygen species generation. PLoS One (2013) 0.92
Emergent role of gasotransmitters in ischemia-reperfusion injury. Med Gas Res (2011) 0.89
Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol (2013) 0.87
H2S during circulatory shock: some unresolved questions. Nitric Oxide (2014) 0.86
Downregulation of cystathionine β-synthase and cystathionine γ-lyase expression stimulates inflammation in kidney ischemia-reperfusion injury. Physiol Rep (2014) 0.86
Hydrogen sulfide: physiological properties and therapeutic potential in ischaemia. Br J Pharmacol (2015) 0.86
Hydrogen sulfide and polysulfides as signaling molecules. Proc Jpn Acad Ser B Phys Biol Sci (2015) 0.85
Hydrogen sulfide to the rescue in obstructive kidney injury. Kidney Int (2014) 0.84
Hydrogen sulfide treatment ameliorates long-term renal dysfunction resulting from prolonged warm renal ischemia-reperfusion injury. Can Urol Assoc J (2014) 0.83
Production of hydrogen sulfide from d-cysteine and its therapeutic potential. Front Endocrinol (Lausanne) (2013) 0.80
Beneficial effects of diminished production of hydrogen sulfide or carbon monoxide on hypertension and renal injury induced by NO withdrawal. Br J Pharmacol (2014) 0.79
Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-induced Matrix Protein Synthesis in Podocytes. J Biol Chem (2015) 0.79
Role of Cystathionine Gamma-Lyase in Immediate Renal Impairment and Inflammatory Response in Acute Ischemic Kidney Injury. Sci Rep (2016) 0.78
Role of Hydrogen Sulfide in Ischemia-Reperfusion Injury. Oxid Med Cell Longev (2015) 0.78
H2S mitigates severe acute pancreatitis through the PI3K/AKT-NF-κB pathway in vivo. World J Gastroenterol (2015) 0.78
Hydrogen sulfide ameliorates the kidney dysfunction and damage in cisplatin-induced nephrotoxicity in rat. Vet Res Forum (2014) 0.77
The summer of hydrogen sulfide: highlights from two international conferences. Med Gas Res (2013) 0.77
Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis. Sci Rep (2016) 0.77
Hydrogen polysulfide (H2S n ) signaling along with hydrogen sulfide (H2S) and nitric oxide (NO). J Neural Transm (Vienna) (2016) 0.77
The Role of Hydrogen Sulfide in Renal System. Front Pharmacol (2016) 0.75
International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol Rev (2017) 0.75
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A (2008) 2.21
Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation (2012) 2.12
GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med (2005) 2.05
Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol (2012) 1.83
On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol (2003) 1.77
Mutations in the pre-replication complex cause Meier-Gorlin syndrome. Nat Genet (2011) 1.74
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J (2002) 1.73
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3beta inhibition. Crit Care Med (2006) 1.66
The inflammatory microenvironment in colorectal neoplasia. PLoS One (2011) 1.62
Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol (2011) 1.62
Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock (2009) 1.60
Peptidoglycan of Staphylococcus aureus causes inflammation and organ injury in the rat. Crit Care Med (2004) 1.57
Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. Crit Care Med (2006) 1.54
Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol (2007) 1.53
Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Int J Cardiol (2011) 1.52
Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med (2003) 1.52
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol (2004) 1.50
Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat. Crit Care Med (2002) 1.49
Refinement of animal models of sepsis and septic shock. Shock (2015) 1.48
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med (2004) 1.48
Primitive hematopoietic stem cells shows a polyclonal pattern in myelodysplastic syndromes. Haematologica (2004) 1.48
Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol (2002) 1.47
Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. Br J Pharmacol (2005) 1.45
Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res (2005) 1.41
Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol (2005) 1.39
Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther (2004) 1.39
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int (2013) 1.37
Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol (2008) 1.32
The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol (2002) 1.29
Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol (2010) 1.28
Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int (2004) 1.26
Biosimilar drugs : concerns and opportunities. BioDrugs (2007) 1.26
Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock (2007) 1.23
Genetic screening in adolescents with steroid-resistant nephrotic syndrome. Kidney Int (2013) 1.21
Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood (2004) 1.21
Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J Clin Invest (2004) 1.17
Dexamethasone ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol (2009) 1.17
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med (2006) 1.16
GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int (2003) 1.16
Update of PAX2 mutations in renal coloboma syndrome and establishment of a locus-specific database. Hum Mutat (2012) 1.15
PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int (2009) 1.15
Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int (2002) 1.15
Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med (2006) 1.14
Molecular and clinical characterization of patients with overlapping 10p deletions. Am J Med Genet A (2010) 1.14
Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock (2004) 1.12
Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol (2010) 1.12
High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock (2004) 1.12
The NLRP3 Inflammasome as a novel player of the intercellular crosstalk in metabolic disorders. Mediators Inflamm (2013) 1.11
Screening for diabetic retinopathy: 1 and 3 nonmydriatic 45-degree digital fundus photographs vs 7 standard early treatment diabetic retinopathy study fields. Am J Ophthalmol (2009) 1.11
Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain. J Neurosci (2003) 1.11
Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am J Respir Crit Care Med (2010) 1.10
The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. Shock (2004) 1.09
Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med (2007) 1.09
Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock (2003) 1.09
Profiling the expression of cytochrome P450 in breast cancer. Histopathology (2010) 1.08
Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock (2006) 1.08
Role of induced nitric oxide in the initiation of the inflammatory response after postischemic injury. Shock (2002) 1.08
A role for the ELAV RNA-binding proteins in neural stem cells: stabilization of Msi1 mRNA. J Cell Sci (2006) 1.07
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol (2003) 1.07